- Home
- PROK vs SABA Comparison
PROK vs SABA Comparison
Compare PROK & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROK | SABA |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | 231 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.5M | 225.6M |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PROK | SABA |
|---|---|---|
| Price | $1.68 | $8.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 682.4K | 55.3K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.54 | $7.96 |
| 52 Week High | $7.13 | $9.46 |
Technical Indicators
Market Signals| Indicator | PROK | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 46.15 |
| Support Level | $1.56 | $8.24 |
| Resistance Level | $2.58 | $8.68 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 22.50 | 14.90 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.